CLDX Q4 2022 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+382.9% YoY

Gross Profit

-$21M-1319.7% margin

Operating Income

-$28M-1728.8% margin

Net Income

-$26M-1642.1% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+296.3%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$353M

Total Liabilities

$27M

Stockholders' Equity

$326M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$334,000	+382.9%
Gross Profit	-$21M	-$14M	-48.4%
Operating Income	-$28M	-$20M	-37.1%
Net Income	-$26M	-$20M	-31.5%

Revenue Segments

Grant

$2M98%

Service

$26,0002%